1.1.1.27: L-lactate dehydrogenase

This is an abbreviated version, for detailed information about L-lactate dehydrogenase, go to the full flat file.

Reaction

(S)-lactate
+
NAD+
=
pyruvate
+
NADH
+
H+

Synonyms

A4-LDH, AdhE, anaerobic lactate dehydrogenase, BbLDH, dehydrogenase, lactate, eLDHA, eLDHB, Epsilon crystallin, epsilon-crystallin, H4-L-lactate dehydrogenase, heart LDH, Immunogenic protein p36, L(+)-nLDH, L-(+)-lactate dehydrogenase, L-lactate dehydrogenase B, L-lactic acid dehydrogenase, L-lactic dehydrogenase, L-LDH, lactate dehydrogenase, lactate dehydrogenase A, lactate dehydrogenase B, lactate dehydrogenase NAD-dependent, lactic acid dehydrogenase, lactic dehydrogenase, LctD, LDH, LDH-1, LDH-2, LDH-3, LDH-4, LDH-5, LDH-A, LDH-A4, LDH-m4, LDH1, LDH2, LdhA, LDHB, mLDH, More, muscle LDH, NAD-lactate dehydrogenase, nitric oxideinducible l-lactate dehydrogenase, PfLDH, proteins, specific or class, anoxic stress response, p34, Sa-LDH-1, TeLdhL, Tsac_0416

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.27 L-lactate dehydrogenase

Inhibitors

Inhibitors on EC 1.1.1.27 - L-lactate dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
(benzylamino)(oxo)acetic acid
(heptylamino)(oxo)acetic acid
(hexylamino)(oxo)acetic acid
(nonylamino)(oxo)acetic acid
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
1,6-dibromo-2-hydroxynaphthalene 3-carboxylic acid
-
0.31 mM
1-[7-[3,4-dihydroxy-2-imino-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-8-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalen-1-yl]ethanone
2,3-dihydroxy-4,6,7-trimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)-7-[4-(trifluoromethyl)benzyl]naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(2-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(3-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(4-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,6-naphthalene disulfonic acid
-
IC50: 21 mM
2,6-naphthalenedicarboxalic acid
-
IC50: 5.1 mM
2-mercaptoethanol
10% inhibition at 1 mM
3,5-dihydroxy 2-naphthoic acid
-
IC50: 1.7 mM
3,5-dihydroxynaphthalene-2-carboxylic acid
3,7-dihydroxy naphthalene-2-carboxylic acid
-
IC50: 2.4 mM
3,7-dihydroxynaphthalene-2-carboxylic acid
3-(3-nitro-4-pyridyl)pyruvate
-
-
-
3-(3-nitropyridin-4-yl)-2-oxopropanoic acid
-
-
3-acetylpyridine adenine dinucleotide
-
the enzyme exhibits characteristic reduced substrate inhibition and enhanced kcat
3-Aminopyridine adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
3-Fluoropyruvate
-
-
3-hydroxy-1,2-oxazole-4-carboxylic acid
-
-
3-hydroxy-1-oxaspiro[4.5]dec-3-en-2-one
-
-
3-hydroxy-2-oxo-1-oxaspiro[4,5]-dec-3-ene
-
-
-
3-nitropropionate
-
-
3-phosphoglycerate
-
-
4,7-dibromo-3-hydroxynaphthalene-2-carboxylic acid
4-(ethylcarbamoyl)benzoic acid
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid
-
-
4-hydroxy-1,2-oxazole-3-carboxylic acid
-
-
6,6'-disulfanediyldipyridine-3-carboxylic acid
6,6'-Dithiodinicotinic acid
-
IC50: 6.6 mM
6-phosphogluconate
-
-
7-(4-chlorobenzyl)-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
8'-acetyl-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8-carboxylic acid
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl acetate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl butanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl pentanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl propanoate
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-(phenylamino)naphthalene-1-sulfonic acid
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-anilino-1-naphthalene sulfonic acid
-
IC50: 0.52 mM
8-[8-acetyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-3,4-dihydroxy-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-2-one
Alpha-NAD+
-
noncompetitive inhibitor versus beta-NAD+
amino(oxo)acetic acid
ascorbate
-
at concentrations normally found in tissue. It is proposed that ascorbate facilitates the storage of glycogen in muscle at rest by inhibiting glycolysis. Aldolase and muscle G-actin protect and reverse inhibition
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')copper
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')zinc
cardiolipin
-
IC50: 0.00005 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
Chloroquine
citrate
-
-
citrate/phosphate buffer
-
at pH 5.4
-
Cu[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, heart, spleen, brain and skeletal muscle tissues, overview
D-fructose 1,6-bisphosphate
D-fructose-1,6-diphosphate
-
5 mM, 25% loss of activity
D-lactate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
dicholesteroyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by dicholesteroyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Exerts profound concentration dependent inhibitory effect on the activity of renal LDH. Inhibitory effect on hepatic LDH is markedly pronounced at 2, 4, 8 and 10 microM. Strongly inhibits cardiac LDH activity when NAD+ is omitted from the pre-incubating medium than when lactate is absent from the pre-incubating medium, significantly inhibits the enzyme activity at 1, 2, 4, and 8 microM
dihydroxyacetone phosphate
-
-
diphenyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by diphenyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Inhibitory effect on hepatic LDH is markedly different at 10 microM. Markedly inhibits cardiac LDH activity at 8 and 10 microM
DTT
19% inhibition at 1 mM
ethyl 3-(3-cyano-4-pyridyl)pyruvate
-
-
-
ethyl 3-(3-cyanopyridin-4-yl)-2-oxopropanoate
-
-
Fe2+
74% inhibition at 1 mM
Fe3+
complete inhibition at 1 mM
fructose 1,6-bisphosphate
fructose 1,6-diphosphate
glucose 6-phosphate
-
-
glutamate
Agama stellio stellio
-
both directions
gossylic nitrile 1,1'-diacetate
gossypol
gossypol lactone
HEPES buffer
-
-
iodoacetamide
iodoacetate
isocitrate
-
-
L-lactate
Lactate analogs
-
-
-
MES buffer
-
-
-
methylmalonate
Mg2+
Agama stellio stellio
-
both directions
NaCl
-
2 M, 36% loss of activity
NADH
-
competitive with respect to NAD+
naphthalene-2,6-dicarboxylic acid
naphthalene-2,6-disulfonic acid
Ni2+
-
partial
nicotinic acid adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
o-phthalaldehyde
-
modification not only results in inactivation of the enzyme, but also leads to the enzyme‘s dissociation and partial unfolding
oxalate
oxaloacetate
oxamate
oxo(pentadecylamino)acetic acid
oxo(phenylamino)acetic acid
oxo[(2-phenylethyl)amino]acetic acid
oxo[(2-phenylpropyl)amino]acetic acid
oxo[(3-phenylpropyl)amino]acetic acid
oxo[(4-phenylbutan-2-yl)amino]acetic acid
oxo[(4-phenylbutyl)amino]acetic acid
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
p-chloromercuribenzoate
p-hydroxymercuribenzoate
Phenylglyoxal
-
-
phosphate
phosphatidylserine
-
IC50: 0.0013 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
phosphoenolpyruvate
pyruvate
SDS
complete inhibition at 0.1%
Sodium phosphate
-
-
Tartronate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
Thionicotinamide adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
Tris/maleate buffer
-
at pH 5.4
-
Urea
-
enzyme activity and electrophoretic pattern of LDH-A4 and malate dehydrogenase, EC 1.1.1.37, compared in relation to heat and urea inactivation, LDH is more sensitive than MDH, overview
Zn[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, and heart, but not in spleen, brain and skeletal muscle tissues, overview
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
[(2-methoxyethyl)amino](oxo)acetic acid
[(3,3-diphenylpropyl)amino](oxo)acetic acid
[(3-methoxypropyl)amino](oxo)acetic acid
[(3-methylbutyl)amino](oxo)acetic acid
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
[(4-chlorobenzyl)amino](oxo)acetic acid
[(4-methylbenzyl)amino](oxo)acetic acid
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
[benzyl(methyl)amino](oxo)acetic acid
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
additional information
-